Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.75 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanide SCHEMBL25383773 | 0.89 | NPC1 (0.79) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL2247517 | 0.86 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL3429444 | 0.85 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL25382711 | 0.84 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL30354780 | 0.84 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL10858025 | 0.82 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL7692504 | 0.82 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL2248644 | 0.79 | NPC1 (1.00) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL5299656 | 0.78 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2LMNAHTT | |
| SCHEMBL2241896 | 0.78 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189477-A1 | Methods and Compositions of P27KIP1 Transcriptional Modulators | NIH-DEITR | 2017-07-06 | — | — | US | claimed |
| US-9572815-B2 | Methods and compositions of p27KIP1 transcriptional modulators | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-02-21 | — | — | US | claimed |
| US-20160030445-A1 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-02-04 | — | — | US | claimed |
| EP-2254572-B1 | COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRM (US) | 2013-10-16 | — | — | EP | claimed |
| EP-2254572-A2 | COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION | Massachusetts Eye & Ear Infirmary (US) | 2010-12-01 | — | — | EP | claimed |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-09-17 | — | — | US | claimed |
| WO-2009100438-A2 | COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-08-13 | — | — | WO | claimed |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2025-03-27 | — | — | US | disclosed |
| US-12239651-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2025-03-04 | — | — | US | disclosed |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-12-03 | — | — | US | disclosed |
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | MASSACHUSETTS EYE AND EAR INFIRMARY | 2024-09-12 | — | — | US | disclosed |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-07-23 | — | — | US | disclosed |
| US-11963968-B2 | Treatment of hearing loss | MASSACHUSETTS EYE AND EAR INFIRMARY (US) | 2024-04-23 | — | — | US | disclosed |
| US-8188131-B2 | Compounds that enhance Atoh1 expression | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188131-B2 | Compounds that enhance Atoh1 expression | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188131-B2 | Compounds that enhance Atoh1 expression | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-09-17 | — | — | US | disclosed |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-09-17 | — | — | US | disclosed |
| WO-2009100438-A2 | COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION | MASSACHUSETTS EYE & EAR INFIRMARY (US) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299432-A1 | TREATMENT OF HEARING LOSS | HES1, NOTCH1, NOTCH4 | NPC1 1607/4885RAB9A 1434/4885SMN1; SMN2 3919/4885 |
| US-12043653-B2 | Efficient delivery of therapeutic molecules to cells of the inner ear | HES1, NOTCH1, NOTCH2 | NPC1 1630/4885RAB9A 2455/4885SMN1; SMN2 4645/4885 |
| US-20170189477-A1 | Methods and Compositions of P27KIP1 Transcriptional Modulators | WNT1, CTNNB1, CTNNBL1 | NPC1 1011/4885RAB9A 4314/4885SMN1; SMN2 4085/4885 |
| US-12156899-B2 | Methods and compositions for regenerating hair cells and/or supporting cells | HES1, NOTCH1, NOTCH4 | NPC1 1656/4885RAB9A 3020/4885SMN1; SMN2 4643/4885 |
| US-20250099539-A1 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS AND/OR SUPPORTING CELLS | HES1, NOTCH1, NOTCH4 | NPC1 1656/4885RAB9A 3020/4885SMN1; SMN2 4643/4885 |
| US-20160030445-A1 | METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTIONAL MODULATORS | WNT1, CTNNB1, CTNNBL1 | NPC1 966/4885RAB9A 4168/4885SMN1; SMN2 4190/4885 |
| US-20090232780-A1 | COMPOUNDS THAT ENHANCE ATOH1 EXPRESSION | DACH1, EZH1, CREBBP | NPC1 1018/4885RAB9A 3293/4885SMN1; SMN2 2179/4885 |
| US-12239651-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | NPC1 1607/4885RAB9A 1434/4885SMN1; SMN2 3919/4885 |
| US-11963968-B2 | Treatment of hearing loss | HES1, NOTCH1, NOTCH4 | NPC1 1607/4885RAB9A 1434/4885SMN1; SMN2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.